GLP Weight Loss Medications
US$ 20.60
benefits of glp-1 coverage in corporate wellness Perspectives from employers on the costs and issues associated with covering agonists for weight loss Perspectives from employers on the
Description
Altimmune just made a big move in the world of GLP-1 research, but this time, its not about obesity.The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD
In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.
Clinical Evidence for GLP-1 Receptor Agonists in Alzheimers Disease. PubMed Cheng HW et al
*Based on peer-reviewed clinical studies
Consumers using the meds were more likely to be between 40 and 64 years of age
In this episode of Longevity by Design, Dr
